RECRUITING

Physician Modified Endovascular Grafts

Description

The primary objectives of this study are to determine whether physician modified endovascular grafts (PMEG) and specified company manufactured devices (all to be referred throughout jointly as the investigational devices) are a safe and effective method of treating patients with elective, symptomatic or ruptured juxtarenal aortic aneurysms in those patients considered to be unsuitable candidates for open surgical repair and have limited or no other options for treatment. Secondary objectives include the validation of a patient-specific, 3-D printed aortic template as a surgical planning tool for fenestrated endografting.

Study Overview

Study Details

Study overview

The primary objectives of this study are to determine whether physician modified endovascular grafts (PMEG) and specified company manufactured devices (all to be referred throughout jointly as the investigational devices) are a safe and effective method of treating patients with elective, symptomatic or ruptured juxtarenal aortic aneurysms in those patients considered to be unsuitable candidates for open surgical repair and have limited or no other options for treatment. Secondary objectives include the validation of a patient-specific, 3-D printed aortic template as a surgical planning tool for fenestrated endografting.

Physician Modified Endovascular Grafts for the Treatment of Elective, Symptomatic or Ruptured Juxtarenal Aortic Aneurysm: an Investigator Initiated Study

Physician Modified Endovascular Grafts

Condition
Abdominal Aortic Aneurysms
Intervention / Treatment

-

Contacts and Locations

Seattle

Harborview Medical Center, Seattle, Washington, United States, 98104

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Patient is \> 18 years of age
  • 2. Patients who are male or non-pregnant female (females of child bearing potential must have a negative pregnancy test prior to enrollment into the study)
  • 3. Patient or Legally Authorized Representative has signed an Institutional Review Board (IRB) approved Informed Consent Form
  • 4. Patient has a juxtarenal abdominal aortic aneurysm that meets at least one of the following:
  • * Abdominal aortic aneurysm \>5.5 cm in diameter
  • * Aneurysm has increased in size by 0.5 cm in last 6 months.
  • * Maximum diameter of aneurysm exceeds 1.5 times the transverse dimension of an adjacent non-aneurysmal aortic segment
  • 5. Patient has patent iliac or femoral arteries that will allow endovascular access with the physician modified endovascular graft.
  • 6. Patient has a suitable non-aneurysmal proximal aortic neck length of \> 2 mm inferior to the most distal renal artery ostium.
  • 7. Patient has a suitable non-aneurysmal distal iliac artery length (seal zone) of \>15 mm. The resultant repair should preserve patency in at least one hypogastric artery.
  • 8. Patient has a suitable non-aneurysmal proximal aortic neck diameter between 20 and 32mm, averaged across the diameters at the Celiac, SMA, at the lowest patent renal artery and at the midpoint of the renal arteries.
  • 9. Patient has suitable non-aneurysmal distal common iliac diameters between 8 and 20 mm.
  • 10. Patient has juxtarenal aortic neck angulation \< 60º
  • 11. Patient must be willing to comply with all required follow-up exam-
  • 1. Patient has a mycotic aneurysm or has an active systemic infection
  • 2. Patient has unstable angina (defined as angina with a progressive increase in symptoms, new onset at rest or nocturnal angina, or onset of prolonged angina)
  • 3. Patient has a major surgical or interventional procedure planned within +/- 30 days of the AAA repair.
  • 4. Patient has history of connective tissue disease (e.g., Marfan's or Ehler's-Danlos syndrome).
  • 5. Patient has a known hypersensitivity or contraindication to anticoagulation or contrast media that is not amenable to pre-treatment.
  • 6. Patient has a known allergy or intolerance stainless steel or gold
  • 7. Patient has a body habitus that would inhibit X-ray visualization of the aorta
  • 8. Patient has a limited life expectancy of less than 1 year
  • 9. Patient is currently participating in another investigational device or drug clinical trial
  • 10. Patient has other medical, social or psychological conditions that, in the opinion of the investigator, preclude them from receiving the pre-treatment, required treatment, and post-treatment procedures and evaluations.
  • 11. Subject is eligible for enrollment in a manufacturer-sponsored IDE at the investigational site

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Washington,

Benjamin W Starnes, MD, PRINCIPAL_INVESTIGATOR, University of Washington

Study Record Dates

2035-01